Navigation Links
Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
Date:1/5/2011

CHAPEL HILL, N.C., Jan. 5, 2011 /PRNewswire/ -- Cempra Pharmaceuticals announced that Carl Foster has been named Executive Vice President of Business Development.  Mr. Foster will be focusing on business development activities related to the company's two lead antibiotic programs, the next-generation fluoroketolide solithromycin (CEM-101), that is in Phase 2 clinical development for community-acquired bacterial pneumonia (CABP), and TAKSTATM (CEM-102 or fusidic acid), that has completed Phase 2 clinical trials for acute bacterial skin and skin structure infections (aBSSSI) including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

Mr. Foster brings with him over 20 years of industry experience in business development and leadership in the biotechnology, pharmaceutical and diagnostic industries. Most recently, Mr. Foster was the Chief Executive Officer of Juilab, a European-based genomics company. Additionally, he held business development positions at several other development-stage biopharmaceutical companies including King Pharmaceuticals, Praecis Pharmaceuticals, Oxford GlycoSciences and Astra Merck.  Mr. Foster has also served as an advisor to pharmaceutical and biotechnology companies as a consultant and as a Managing Director with Ferghana Partners, Inc., an international investment banking group in New York City.

"Mr. Foster has a proven track record of success in business development," said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra Pharmaceuticals. "He has extensive experience leading successful pharmaceutical development efforts to help companies maximize their portfolio's potential and capitalize on growth opportunities. His contribution will be vital because of the mid-clinical-stage status of our programs for solithromycin and TAKSTA."

Mr. Foster added, "Cempra's two lead antibiotic candidates not only have a significant commercial potential but also may help fulfill the need for new and effective antibiotics. Solithromycin and TAKSTA have the potential to treat CABP and aBSSSI, respectively. I am excited about the products we have to offer and I look forward to helping Cempra bring these two products to market."  

About Cempra PharmaceuticalsFounded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.Media Contacts:Russo Partners, LLCRobert E. Flamm, Ph.D.(212) 845-4226 Robert.flamm@russopartnersllc.com Tony Russo, Ph.D.(212) 845-4251Tony.russo@russopartnersllc.com
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
2. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
4. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
5. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
6. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
7. Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 12
8. MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
10. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
11. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Research and Markets has announced the addition of the "Hemophilia ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... questions: What are the key drugs marketed ... Global Hemophilia market? What are the unit prices and ...
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... Feb. 23, 2017  Directors from Pharma To Market Pty Ltd ... joined forces, resulting in the founding of Pharma To Market Pte ... To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... the Singapore based entity. Joelle brings with ...
Breaking Medicine Technology:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Elisa Guajardo Carothers is not your typical ... to studying to become a nun. Now, she writes about God, when she isn’t swimming ... Know BC and AD, Here is BS! (Before Satan),” she offers a comedic look at ...
(Date:2/27/2017)... N. Y. (PRWEB) , ... February 27, 2017 , ... ... ( ILADS ) has disclosed that despite scientific studies, the Center for Disease Control ... chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into a ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... an upgrade to the company's Yelp listing. Bay Area residents struggling from thinning ... as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an extension of ... to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house dust mite ... globally recognised standard that sets out requirements for the technical competence of testing ...
(Date:2/26/2017)... (PRWEB) , ... February 26, ... ... sets a new technology standard in staffing, scheduling, and reporting for healthcare ... and predict activity throughout the entire staffing process. StaffBridge technology improves staffing ...
Breaking Medicine News(10 mins):